Hope for aggressive breast cancer. Survivors and doctors discuss breakthroughs, fears, and the need for inclusive research.

The first patient has been enrolled in the phase 3 PROSTATE-IQ trial being conducted in men with prostate cancer recurrence ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

Grifols has announced positive results from its phase 2/3 clinical trial evaluating the efficacy and safety of intravenous ...

In this episode of Denatured, BioSpace's Head of Insights Lori Ellis and Miruna Sasu, CEO of COTA, discuss the challenges of ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Patients enroll in phase 2 oncology trials seeking access to promising new treatments, but the risk-benefit assessments and ...

The study will measure the impact of Cognixion's novel combination of BCI, AI and AR technology on the ability of amyotrophic lateral sclerosis ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...